3,500
Participants
Start Date
May 24, 2024
Primary Completion Date
September 29, 2028
Study Completion Date
September 29, 2028
CAB LA
Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
RECRUITING
GSK Investigational Site, Entebbe
RECRUITING
GSK Investigational Site, Chitungwiza
RECRUITING
GSK Investigational Site, City of Cape Town
RECRUITING
GSK Investigational Site, City of Cape Town
RECRUITING
GSK Investigational Site, Buenos Aires
RECRUITING
GSK Investigational Site, City of Johannesburg
RECRUITING
GSK Investigational Site, Durban
RECRUITING
GSK Investigational Site, Isipingo
RECRUITING
GSK Investigational Site, Durban
RECRUITING
GSK Investigational Site, Cape Town
RECRUITING
GSK Investigational Site, Sol Plaatjie
RECRUITING
GSK Investigational Site, Pathum Wan
RECRUITING
GSK Investigational Site, Lima
RECRUITING
GSK Investigational Site, Lima
RECRUITING
GSK Investigational Site, Lima
RECRUITING
GSK Investigational Site, Piura
RECRUITING
GSK Investigational Site, Kisumu
RECRUITING
GSK Investigational Site, Chiang Mai
RECRUITING
GSK Investigational Site, Chitungwiza
RECRUITING
GSK Investigational Site, Almagro
RECRUITING
GSK Investigational Site, Francistown
RECRUITING
GSK Investigational Site, Blantyre
RECRUITING
GSK Investigational Site, Kampala
RECRUITING
GSK Investigational Site, Kampala
RECRUITING
GSK Investigational Site, Harare
RECRUITING
GSK Investigational Site, Harare
RECRUITING
GSK Investigational Site, Porto Alegre
RECRUITING
GSK Investigational Site, Rio de Janeiro
RECRUITING
GSK Investigational Site, São Paulo
RECRUITING
GSK Investigational Site, São Paulo
RECRUITING
GSK Investigational Site, Mbabane
RECRUITING
GSK Investigational Site, Lilongwe
RECRUITING
GSK Investigational Site, Lima
RECRUITING
GSK Investigational Site, Chitungwiza
Lead Sponsor
Collaborators (2)
GlaxoSmithKline
INDUSTRY
PPD Development, LP
INDUSTRY
ViiV Healthcare
INDUSTRY